Chronic Lymphocytic Leukemia

Chronic Lymphocytic Leukemia

GENUINE Improvements: Ublituximab Plus Ibrutinib for CLL

Results from the phase 3 GENUINE trial show that ublituximab plus ibrutinib is superior to ibrutinib alone for patients with relapsed or refractory high-risk CLL.

Ustekinumab-Induced Chronic Lymphocytic Leukemia in a Patient With Psoriatic Arthritis

This is a case report on the development of chronic lymphocytic leukemia in a patient with PsA treated with ustekinumab.

Therapeutic Options for Patients with TP53 Deficient Chronic Lymphocytic Leukemia

Treatment of patients with CLL harbouring TP53-deficiency requires drugs that promote cell death independently of TP53. 

Cancer Management and Research

Tissue Factor Pathway Inhibitor Upregulates CXCR7 Expression and Enhances CXCL12-Mediated Migration in Chronic Lymphocytic Leukemia

This study aims to explore the role of TFPI in CXCL12-mediated migration of CLL cells.

Scientific Reports
Responses to Conjugate Pneumococcal Vaccine in Patients With Chronic Lymphocytic Leukemia

Mauro et al found that only a small minority of patients with CLL developed an adequate immune response to pneumococcal vaccination, with response being more likely in patients who...

The ASCO Post
Proteomic and Bioinformatic Profiling of Neutrophils in CLL Reveals Functional Defects That Predispose to Bacterial Infections

This study describes a molecular signature of neutrophils through proteomic, bioinformatic, and functional analyses linked to a reduced migratory ability, that could lead to increased...

Blood Advances
Zanubrutinib (BGB-3111), a Second-Generation Selective Covalent Inhibitor of Bruton’s Tyrosine Kinase and Its Utility in Treating Chronic Lymphocytic Leukemia

Long-term follow-up is needed, but zanubrutinib holds promise to be an effective therapy for CLL with a manageable side effect profile and will be an exciting addition to the treatment paradigm.

Drug Design, Development and Therapy
Preclinical Evaluation of the Hsp90 Inhibitor SNX-5422 in Ibrutinib Resistant CLL

This study explores the efficacy of the Hsp90 inhibitor, SNX-5422, in CLL.

Journal of Hematology & Oncology
Non-Coding RNAs: The “Dark Side Matter” of the CLL Universe

This review summarizes the main ncRNAs discovered in CLL and the molecular mechanisms by which they are affected and how they influence the development and the progression of the disease.

Assessing Technical and Biological Variation in SWATH-MS-Based Proteomic Analysis of Chronic Lymphocytic Leukaemia Cells

This study provides a valuable resource for researchers working on the proteomics of CLL.

Scientific Reports
The Role of Acalabrutinib in Adults With Chronic Lymphocytic Leukemia

The two major classes of drugs that have contributed to this dramatic evolution include the Bruton tyrosine kinase inhibitors and BCL2 inhibitors.

Therapeutic Advances in Hematology
An Unusual Case of Prolymphocytic Leukemia Transformation in a Patient With Chronic Lymphocytic Leukemia

This case recapitulates the challenges in diagnosing and treating B-PLL. 

Journal of Investigative Medicine High Impact Case Reports
Low Expression of ZHX1 and ZHX2 Impacts on the Prognosis of Chronic Lymphocytic Leukemia

This study determines whether the altered expression of ZHX1 and ZHX2 has clinical implications in patients with CLL.

Genome-Wide Association Study Identifies Risk Loci for Progressive Chronic Lymphocytic Leukemia

This work identifies rs736456 and rs3778076 as prognostic in CLL, demonstrating that disease progression is determined by constitutional genetic variation as well as known somatic drivers.

T Cells in Chronic Lymphocytic Leukemia: A Two-Edged Sword

The T cells in CLL exhibit a distinctive phenotype with features of “exhaustion” likely as a result of chronic antigenic stimulation.

Frontiers in Immunology
Phosphoinositide 3-Kinase Signaling in the Tumor Microenvironment: What Do We Need to Consider When Treating Chronic Lymphocytic Leukemia With PI3K Inhibitors?

This review outlines the impacts of PI3K inhibition on the tumor microenvironment with a specific focus on CLL.

Frontiers in Immunology
Telomere Dysfunction in Chronic Lymphocytic Leukemia

In chronic lymphocytic leukemia, telomere length is an independent prognostic factor and short telomeres are associated with adverse outcome.

Frontiers in Oncology
HELQ and EGR3 Expression Correlate With IGHV Mutation Status and Prognosis in Chronic Lymphocytic Leukemia

This study investigates the transcriptomic signatures associating with IGHV mutation status and CLL prognosis.

Oncologist and Patient Preferences for Novel Agents in First-Line Treatment for Chronic Lymphocytic Leukemia: Commonalities and Disconnects

The purpose of this study is to understand how variations in attributes impact treatment choice among patients and oncologists.

May Ibrutinib Have Activity in Respiratory Complications by SARS-CoV-2? Clinical Experience in a Patient with Chronic Lymphocytic Leukemia

Study investigators present our clinical experience about ibrutinib use in ARDS secondary to SARS-CoV-2 in a patient with chronic lymphocytic leukemia.

Recurrent XPO1 Mutations Alter Pathogenesis of Chronic Lymphocytic Leukemia

Exportin 1 is a key mediator of nuclear export with relevance to multiple cancers, including chronic lymphocytic leukemia.

The Calcitriol/Vitamin D Receptor System Regulates Key Immune Signaling Pathways in Chronic Lymphocytic Leukemia

This study seeks to obtain deeper biological insight into the role of vitamin D in the pathophysiology of CLL.

Enhanced Expression of miR-181b in B Cells of CLL Improves the Anti-Tumor Cytotoxic T Cell Response

Low expression of miR-181b in chronic lymphocytic leukemia is linked to progression and cell death resistance.

Deciphering the Complex Circulating Immune Cell Microenvironment in Chronic Lymphocytic Leukaemia Using Patient Similarity Networks

This study reveals high inter-individual heterogeneity in the distribution and activation of bystander immune cells in CLL, depending on the bulk of the CLL cells.

Scientific Reports
Concurrent BK Polyomavirus, Adenovirus and Cytomegalovirus Infections in a Patient Treated for Chronic Lymphocytic Leukaemia

This case represents a diagnostic and therapeutic challenge due to the multiple concurrent viral infections causing haematuria as well as the combined...

Overcoming Resistance to Targeted Therapies in Chronic Lymphocytic Leukemia

Recent advances that have contributed to the understanding of resistance to targeted therapies in CLL are discussed in this study.

Blood Advances
FcγRIIb-BCR Coligation Inhibits B-cell Receptor Signaling in Chronic Lymphocytic Leukemia

Considering the major role of BCR in the pathogenesis of CLL and the activated nature of the leukemic cells, this study investigates whether FcγRIIb could regulate BCR signaling...

Genomic Arrays Identify High-Risk Chronic Lymphocytic Leukemia With Genomic Complexity

Complex karyotype identified by chromosome-banding analysis has been shown to have prognostic value in chronic lymphocytic leukemia.

Analysis of Retrotransposon Subfamily DNA Methylation Reveals Novel Early Epigenetic Changes in Chronic Lymphocytic Leukemia

While global hypomethylation of these elements has been widely reported in solid tumors, their epigenetic dysregulation is yet to be characterized in CLL, and...

Current Progress in CAR-T Cell Therapy for Hematological Malignancies

Chimeric antigen receptor T cells therapy was an efficacious therapeutic approach treating hematological malignancies and encouraging results have been achieved.

EHA Endorsement of ESMO Clinical Practice Guidelines for Diagnosis, Treatment, and Follow-up of Chronic Lymphocytic Leukemia

European Hematology Association and ESMO recently agreed to collaborate on the production of European Guidelines for different hematological malignancies.

Refractory Chronic Lymphocytic Leukemia with Central Nervous System Involvement

There have been few reports on central nervous system involvement in chronic lymphocytic leukemia.

Longitudinal CITE-Seq profiling of chronic lymphocytic leukemia during ibrutinib treatment: evolution of leukemic and immune cells at relapse

Ibrutinib, an irreversible BTK inhibitor, has revolutionized CLL treatment, but resistances to ibrutinib have emerged, whether related or not to BTK mutations.

Approaches for relapsed CLL after chemotherapy-free frontline regimens

Novel agents, including Bruton’s tyrosine kinase inhibitors have fundamentally changed the CLL treatment landscape, allowing for a chemotherapy-free paradigm for many.

Systems biology drug screening identifies statins as enhancers of current therapies in chronic lymphocytic leukemia

Study results highlight the possibility of repurposing widely used drugs such as statins to target the microenvironment and to improve the efficacy of ibrutinib or venetoclax in CLL cells.

Scientific Reports
Preventing and monitoring for tumor lysis syndrome and other toxicities of venetoclax during treatment of chronic lymphocytic leukemia

Recent developments in the management of CLL have moved the standard of care away from chemoimmunotherapy to targeted agents such as oral kinase inhibitors or...

Highly Sensitive and Accurate Assessment of Minimal Residual Disease in Chronic Lymphocytic Leukemia Using the Novel CD160-ROR1 Assay

This study investigated a flow cytometric assay targeting the tumor-specific antigens CD160 and receptor tyrosine kinase-like orphan receptor 1, along with...

Frontiers in Oncology
Standard treatment approaches for relapsed/refractory chronic lymphocytic leukemia after frontline chemoimmunotherapy

In this article, the management of patients with relapsed/refractory CLL is discussed, with a particular emphasis on the role of PIs.

Aniline-containing derivatives of parthenolide: Synthesis and anti-chronic lymphocytic leukaemia activity

Parthenolide exhibits anti-leukaemia activity, whilst its synthetic modification to impart improve drug-like properties, including 1,4-conjugate addition of primary and...

Chronic lymphocytic leukemias with trisomy 12 show a distinct DNA methylation profile linked to altered chromatin activation

The landscape of genetic alterations of CLL is well characterized and found to be extremely heterogeneous, with multiple chromosomal aberrations and dozens of driver genes...

Three-Year Follow-Up of Triplet Therapy Results in High Responses Among CLL Patients

The combination of fixed duration obinutuzumab, ibrutinib, and venetoclax led to high rates of overall response and undetectable minimal residual disease in CLL patients...

Oncology Times - Latest Articles
Driver Mutations and Single Copy Number Abnormalities Identify Binet Stage A Patients with Chronic Lymphocytic Leukemia with Aggressive Progression

The correlation between progression and the genetic characteristics of Binet stage A patients with CLL detected by whole exome sequencing was analyzed in 55 patients.

Chronic Lymphocytic Leukemia-Induced Humoral Immunosuppression: A Systematic Review

The aim of the study was to review the available literature data on patients with CLL, with particular regard to the pathogenesis of the disease and the impact of...

Method for the Analysis of the Tumor Microenvironment by Mass Cytometry: Application to Chronic Lymphocytic Leukemia

In this methods article, the authors provide a detailed protocol for the staining of CLL TME cells aiming at their characterization using mass cytometry.

Frontiers in Immunology
Evolution of Advanced Chronic Lymphoid Leukemia Unveiled by Single-Cell Transcriptomics: A Case Report

This study applied single-cell RNA-seq to a CLL case, sampled at diagnosis and relapse, that was treated with FCR and underwent...

Frontiers in Oncology
Prognostic impact of prevalent chronic lymphocytic leukemia stereotyped subsets

This study assessed the associations and prognostic value of these BcR IG in prospective multicenter clinical trials reflective of two different clinical situations...

Expanded and activated allogeneic NK cells are cytotoxic against B-chronic lymphocytic leukemia (B-CLL) cells with sporadic cases of resistance

In the present work, using an optimized expansion/activation protocol of human NK cells, the authors generate expanded NK cells with increased expression of CD56 and...

Scientific Reports
Time to first treatment and P53 dysfunction in chronic lymphocytic leukaemia: results of the O-CLL1 study in early stage patients

TP53 mutations and deletions of the corresponding locus [del(17p)] were evaluated in 469 cases from the O-CLL1 observational study that recruited a cohort of clinically and...

Scientific Reports
Genomic and transcriptomic correlates of Richter's transformation in Chronic Lymphocytic Leukemia.

This study conducted whole genome sequencing of paired circulating CLL (PB-CLL) and RS biopsies (tissue-RS) from 17 clinical trial (CHOP-O) patients.

The role of 18F-FDG-PET in detecting Richter transformation of chronic lymphocytic leukemia in patients receiving therapy with a B-cell receptor inhibitor

In CLL patients with suspected disease progression, distinguishing between progressive CLL and RT is critically important, as the management and prognosis are different.

Successful application of anti-CD19 CAR-T therapy with IL-6 knocking down to patients with central nervous system B-cell acute lymphocytic leukemia

In this study, CAR-Ts targeting CD19 with short hairpin RNA (shRNA)-IL-6 gene silencing technology were prepared.

Translational Oncology
Zanubrutinib monotherapy for patients with treatment naïve chronic lymphocytic leukemia and 17p deletion

Zanubrutinib is a selective next-generation Bruton tyrosine kinase inhibitor. The study evaluated the safety and efficacy of zanubrutinib 160 mg twice daily in treatment-naïve patients...

DAP Kinase-Related Apoptosis-Inducing Protein Kinase 2 (DRAK2) Is a Key Regulator and Molecular Marker in Chronic Lymphocytic Leukemia.

An impaired balance between pro- anti-apoptotic stimuli determines chemorefractoriness outcome. The low proliferation rate CLL cells indicates that one primary mechanisms involved...

International Journal of Molecular Sciences
An update of venetoclax and obinutuzumab in chronic lymphocytic leukemia.

In the last decade, treatment of chronic lymphocytic leukemia has shifted away from chemoimmunotherapy toward targeted novel agents such as small molecule inhibitors and antibodies. 

Future Oncology
Evaluating Fidelity of reporting in randomized controlled trials on childhood acute lymphocytic leukemia

The aim of this study is to evaluate adherence of RCTs involving acute lymphocytic leukemia to the TIDieR checklist.

Applied Cancer Research
Wnt5a enhances proliferation of chronic lymphocytic leukemia and ERK1/2 phosphorylation via a ROR1/DOCK2-dependent mechanism.

This study demonstrates that Wnt5a can induce activation of ERK1/2 and enhance CLL-cell proliferation via a ROR1/DOCK2-dependent pathway independent of BTK.

Zanubrutinib (BGB-3111) plus obinutuzumab in patients with chronic lymphocytic leukemia and follicular lymphoma.

In this phase 1b study, zanubrutinib was tolerable at 160 mg twice daily or 320 mg once daily combined with IV obinutuzumab in patients with CLL/SLL and FL.

Blood Advances
Pathological RANK signaling in B cells drives autoimmunity and chronic lymphocytic leukemia.

Clinical evidence suggests alterations in receptor activator of NF-κB signaling are key contributors to B cell autoimmunity and malignancy, but the pathophysiological consequences of...

Journal of Experimental Medicine
SHC014748M, a novel selective inhi-bitor of PI3Kδ, demonstrates promising preclinical antitumor activity in B cell lymphomas and chronic lymphocytic leukemia

This study comprehensively evaluated the in vitro and in vivo antitumor activity of SHC014748M, an oral selective inhibitor of PI3Kδ under Phase I clinical evaluation.

Ibrutinib treatment via alternative administration in a patient with chronic lymphocytic leukemia and dysphagia.

This study reports on the utilization and clinical outcomes associated with alternative administration of ibrutinib capsules in a patient with chronic lymphocytic leukemia and significant dysphagia

Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners
Raman spectroscopy-based biomarker screening by studying the fingerprint characteristics of chronic lymphocytic leukemia and diffuse large B-cell lymphoma

This exploratory study primarily demonstrated the great potential of developing RS blood plasma analysis as a novel clinical tool for the noninvasive detection of DLBCL and CLL.

Journal of Pharmaceutical and Biomedical Analysis
Real-world analysis of treatment patterns and clinical outcomes in patients with newly diagnosed chronic lymphocytic leukemia from seven Latin American countries

The purpose of this study was to describe chronic lymphocytic leukemia treatment patterns and patient outcomes in Latin America.

Effect of Ibrutinib on the IFN Response of Chronic Lymphocytic Leukemia Cells.

The Bruton's tyrosine kinase inhibitor ibrutinib has profound activity in chronic lymphocytic leukemia but limited curative potential by itself. 

Journal of Immunology

source list reference